vs
Side-by-side financial comparison of Volato Group, Inc. (SOAR) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Volato Group, Inc. is the larger business by last-quarter revenue ($24.9M vs $13.7M, roughly 1.8× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 14.5%, a 61.2% gap on every dollar of revenue.
Volato Aeronaves also known as Volato Aeronaves e Compósitos Ltda is a Brazilian aircraft manufacturer.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
SOAR vs XLO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.9M | $13.7M |
| Net Profit | $3.6M | $10.4M |
| Gross Margin | 15.2% | — |
| Operating Margin | 3.5% | -86.5% |
| Net Margin | 14.5% | 75.7% |
| Revenue YoY | 13632.0% | — |
| Net Profit YoY | 121.3% | 179.1% |
| EPS (diluted) | $0.75 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.7M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | $24.9M | $8.1M | ||
| Q1 25 | $25.5M | $2.9M | ||
| Q3 24 | $38.5M | — | ||
| Q4 23 | $3.2M | — | ||
| Q3 23 | $3.7M | — | ||
| Q2 23 | $13.0M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | $3.6M | $-15.8M | ||
| Q1 25 | $455.0K | $-13.3M | ||
| Q3 24 | $-4.4M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-11.8M | — | ||
| Q2 23 | $-9.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.2% | — | ||
| Q1 25 | 17.6% | — | ||
| Q3 24 | 16.6% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 8.7% | — | ||
| Q2 23 | -24.2% | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | 3.5% | -177.7% | ||
| Q1 25 | 9.9% | -472.7% | ||
| Q3 24 | 5.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -50.2% | — | ||
| Q2 23 | -71.3% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | — | -85.4% | ||
| Q2 25 | 14.5% | -196.0% | ||
| Q1 25 | 1.8% | -452.7% | ||
| Q3 24 | -11.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -323.6% | — | ||
| Q2 23 | -75.8% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | $0.75 | $-0.16 | ||
| Q1 25 | $0.03 | $-0.18 | ||
| Q3 24 | $-3.76 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-0.71 | — | ||
| Q2 23 | $-0.86 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-7.1M | $35.3M |
| Total Assets | $13.0M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $35.3M | ||
| Q3 25 | — | $-8.1M | ||
| Q2 25 | $-7.1M | $7.1M | ||
| Q1 25 | $-15.8M | $10.7M | ||
| Q3 24 | $-19.6M | — | ||
| Q4 23 | $14.8M | — | ||
| Q3 23 | $-34.8M | — | ||
| Q2 23 | $-23.0M | — |
| Q4 25 | — | $154.7M | ||
| Q3 25 | — | $133.7M | ||
| Q2 25 | $13.0M | $133.8M | ||
| Q1 25 | $23.4M | $103.7M | ||
| Q3 24 | $47.9M | — | ||
| Q4 23 | $71.7M | — | ||
| Q3 23 | $70.4M | — | ||
| Q2 23 | $70.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $848.0K | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.7% |
| Cash ConversionOCF / Net Profit | 0.24× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | $848.0K | $-14.5M | ||
| Q1 25 | $-312.0K | $29.0M | ||
| Q3 24 | $-3.1M | — | ||
| Q4 23 | $-30.4M | — | ||
| Q3 23 | $-10.9M | — | ||
| Q2 23 | $-5.6M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | $-3.2M | — | ||
| Q4 23 | $-31.0M | — | ||
| Q3 23 | $-11.1M | — | ||
| Q2 23 | $-5.9M | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q3 24 | -8.2% | — | ||
| Q4 23 | -958.0% | — | ||
| Q3 23 | -304.7% | — | ||
| Q2 23 | -45.6% | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q3 24 | 0.1% | — | ||
| Q4 23 | 19.7% | — | ||
| Q3 23 | 7.4% | — | ||
| Q2 23 | 2.2% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | -0.69× | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
